Regulatory Risk Intensifies: 2025 EPS guidance of $6.15-$6.35 is explicitly contingent on favorable FCG depreciation study outcome, elevating execution risk and regulatory dependency as material factors for earnings delivery Significant CapEx Escalation: Capital expenditures increased to $425-$450 million guidance range, driven primarily by multi-year ERP system implementation, representing…

Our analysis rates this filing BULLISH. The low concern level (2.5/10) reflects a fundamentally strong quarter with minimal incremental risks. The company delivered solid earnings growth (5.1% EPS growth, 8.0% adjusted YTD), demonstrated margin expansion with double-digit gross margin increases,…

Concern level: MODERATE (2.5/10). Key factors: 2025 EPS guidance ($6.15-$6.35) explicitly contingent on FCG depreciation study regulatory approval; Capital expenditure requirements increased to $425-$450 million range for 2025; Recent equity issuance diluted EPS by $0.04 per share in Q3 2025.

Notable risk changes: 2025 EPS guidance ($6.15-$6.35) explicitly conditioned on successful FCG depreciation study outcome - regulatory dependency now highlighted; 2025 capital expenditure guidance increased from prior range to $425-$450 million, primarily for multi-year ERP system implementation; Company issued $92 million in equity over last twelve months to restore balance sheet ratios, diluting EPS by $0.04 per…

The model predicts CPK will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.